ReviewOne health (Amsterdam, Netherlands)2025
From forest to frontline: A comprehensive review of Mpox's global leap and viral evolution (2022-2024).
Review in One health (Amsterdam, Netherlands), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- A comprehensive overview of monkeypox virus disease.Tropical medicine and health · 2026Review
- Mpox in Europe, 2022-2026: A Scoping Review of Viral Clades, Host Determinants of Severity and Antiviral Therapy.Viruses · 2026Article
- From behavioral to structural correlates: a multi-phase analysis of global reported mpox.BMC medicine · 2026Article
- Monkeypox Virus (MPXV) Transmission Dynamics in Neighboring Countries as a Potential Threat to Kazakhstan.Viruses · 2026Review
- Risk Assessment Method for Global Monkeypox Importation into China - May 2022-September 2025.China CDC weekly · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Since 2022, the global epidemiology of Mpox (MPXV) has transformed, with Clade IIb driving widespread transmission in non-endemic regions and Clade I resurging across Central Africa. Genomic adaptations, such as APOBEC3 mutations, and increasing human-to-human transmission have raised public health alarms. This review synthesizes the latest evidence on Clade I and Clade II MPXV outbreaks from 2022 to 2024, with an emphasis on geographic expansion, demographic disparities, and systemic response gaps. Methods: A comprehensive literature search was conducted between September and December 2024 using PubMed, CDC, WHO, and ECDC databases. Studies were included if they reported primary data on Clade I or Clade II MPXV epidemiology. Gray literature, including public health reports and situation summaries, was also analyzed. Data extraction focused on demographic trends, transmission modes, genomic mutations, and public health responses. Results: Fifty-one sources were reviewed, including 14 peer-reviewed articles and 37 Gy literature reports. Clade IIb accounted for 117,000+ cases across 123 countries, primarily affecting men who have sex with men (MSM). Clade I resurged in the Democratic Republic of the Congo (DRC) with over 19,000 confirmed cases and 975 deaths, disproportionately affecting children under five. APOBEC3-type mutations were linked to increased Clade I transmissibility. International spread of Clade I was reported in the U.S., Europe, and Asia. Diagnostic limitations, especially in the DRC, and gaps in pediatric vaccine access remain major challenges. Conclusion: MPXV's global trajectory now includes sustained transmission of both Clades I and II. Expanded genomic surveillance, pediatric-focused outbreak response, and equitable diagnostic and vaccine access are urgently needed. A One Health approach is essential to address evolving viral behavior and health disparities in endemic and non-endemic regions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.